Black Rock Inc. Gain Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 84,620 shares of GANX stock, worth $153,162. This represents 0.0% of its overall portfolio holdings.

Number of Shares

84,620

Previous 75,398 12.23%

Holding current value

$153,162

Previous $284,000 61.97%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.24 - $3.99 $11,435 - $36,795	9,222 Added 12.23%	84,620 $108,000
Q1 2024 May 10, 2024	BUY	$3.21 - $5.04 $153,396 - $240,846	47,787 Added 173.07%	75,398 $284,000
Q4 2023 Feb 13, 2024	SELL	$2.07 - $3.4 $649 - $1,067	-314 Reduced 1.12%	27,611 $90,000
Q3 2023 Nov 13, 2023	SELL	$3.19 - $4.68 $3,505 - $5,143	-1,099 Reduced 3.79%	27,925 $91,000
Q2 2023 Aug 11, 2023	BUY	$4.36 - $5.5 $18,512 - $23,353	4,246 Added 17.14%	29,024 $130,000
Q1 2023 May 12, 2023	SELL	$3.18 - $5.16 $642 - $1,042	-202 Reduced 0.81%	24,778 $119,000
Q4 2022 Feb 13, 2023	BUY	$2.89 - $3.35 $6,008 - $6,964	2,079 Added 9.08%	24,980 $78,000
Q3 2022 Nov 14, 2022	SELL	$3.17 - $4.21 $2,028 - $2,694	-640 Reduced 2.72%	22,901 $75,000
Q2 2022 Aug 12, 2022	BUY	$2.56 - $4.56 $33,034 - $58,842	12,904 Added 121.31%	23,541 $85,000
Q1 2022 May 12, 2022	SELL	$3.15 - $5.59 $1,644 - $2,917	-522 Reduced 4.68%	10,637 $43,000
Q4 2021 Feb 10, 2022	SELL	$5.3 - $9.24 $1,680 - $2,929	-317 Reduced 2.76%	11,159 $60,000
Q3 2021 Nov 09, 2021	SELL	$7.01 - $10.26 $1,282 - $1,877	-183 Reduced 1.57%	11,476 $85,000
Q2 2021 Aug 11, 2021	BUY	$8.96 - $15.8 $104,464 - $184,212	11,659 New	11,659 $116,000

Others Institutions Holding GANX

# of Institutions

Shares Held

4.47M

Call Options Held

37.9K

Put Options Held

View Full List

About Gain Therapeutics, Inc.

Ticker GANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,883,400
Market Cap $21.5M
Description
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...

More about GANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account